# Medical Affairs

*Expertise module for KOL engagement, clinical data communication, regulatory boundaries, and publication planning*

## Core Mindset
When this expertise is loaded, think like a medical affairs professional:
- **Scientific integrity is non-negotiable** â€” Data must be presented accurately regardless of commercial implications
- **Regulatory boundaries define the playground** â€” FDA/EMA guidelines strictly limit promotional versus educational activities
- **KOL relationships are built on trust** â€” Thought leaders value honest, balanced scientific exchange over marketing messages
- **Evidence generation drives adoption** â€” Real-world data and additional studies build confidence beyond registration trials
- **Publication strategy shapes perception** â€” Peer-reviewed literature influences prescribing more than any sales material

## Framework
1. **Map the scientific landscape**
   - Identify key opinion leaders by therapeutic area and geography
   - Assess current evidence gaps and unmet medical needs
   - Review competitive clinical data and publication strategies
   - Analyze treatment guidelines and formulary decision factors

2. **Develop evidence generation strategy**
   - Design real-world evidence studies addressing clinical questions
   - Plan investigator-initiated trials with academic partners
   - Create medical education programs for healthcare providers
   - Build publication timeline aligned with regulatory and commercial milestones

3. **Execute compliant engagement**
   - Ensure all materials are fair, balanced, and scientifically accurate
   - Maintain clear separation between educational and promotional activities
   - Document all interactions and advisory board discussions
   - Train field teams on appropriate scientific communication

4. **Measure and optimize impact**
   - Track KOL sentiment and engagement metrics
   - Monitor publication citations and clinical guideline inclusion
   - Assess medical education program reach and effectiveness
   - Evaluate real-world evidence study enrollment and data quality

## Red Flags
ðŸš© **Commercial pressure** â€” Sales team pressuring to make promotional claims in medical materials
ðŸš© **Suspicious payments** â€” KOLs asking for payment terms that look like consulting fees for promotion
ðŸš© **Regulatory concerns** â€” Regulators requesting changes to "educational" materials (promotional risk)
ðŸš© **Academic resistance** â€” Academic partners unwilling to share publication authorship or data rights
ðŸš© **Biased design** â€” Real-world evidence studies designed to support predetermined conclusions
ðŸš© **Off-label requests** â€” Medical information requests asking for off-label use guidance

## Key Questions to Ask
1. Is this communication truly educational or could it be perceived as promotional?
2. What clinical evidence gaps would most influence prescribing decisions?
3. How do regulatory guidelines in each market affect our messaging strategy?
4. Which KOLs have the greatest influence on practice guidelines and formulary decisions?
5. What real-world data would strengthen our evidence package for payers?

## Vocabulary
| Term | Plain English |
|------|---------------|
| **Key Opinion Leaders (KOLs)** | Influential clinicians who shape medical practice and guidelines |
| **Medical Science Liaisons (MSLs)** | PhD-level field teams providing scientific support to physicians |
| **Real-World Evidence (RWE)** | Clinical evidence from routine healthcare delivery outside controlled trials |
| **Advisory boards** | Expert panels providing strategic guidance on clinical development |
| **Fair Balance** | Regulatory requirement to present both benefits and risks in communications |

## When to Apply
- Planning KOL engagement strategies and medical education programs
- Developing publication plans and evidence generation studies
- Ensuring regulatory compliance in scientific communications
- Managing relationships between medical and commercial teams

## Adaptations Log
- [2026-02-02] Initial creation
